Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

68.51 +0.81 (+1.20%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy. 
Via Stocktwits
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Wegovy, Zepbound Just Got Cheaper: Cigna Sets $200 Monthly Limit For Weight-Loss Drug Users
Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound 
Via Stocktwits
Best Healthcare Stocks: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Novo Nordisk Stock Popped on Tuesday
If you can't beat Novo Nordisk, maybe you should join 'em? 
Via The Motley Fool
2 Fantastic Beaten-Down Growth Stocks Down 40% and 45% to Buy
These two stocks are poised for near-term and long-term upside. 
Via The Motley Fool
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants... 
Via Benzinga
MarketBeat Week in Review – 05/12 - 05/16
Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts 
Via MarketBeat
Topics Artificial Intelligence Economy Government
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Technical Breakout Potential
NOVO-NORDISK (NYSE:NVO) is a strong growth stock with solid fundamentals and a promising technical setup, offering potential for a breakout. 
Via Chartmill
On Holding on Fire
A consumer goods company hit 40% yearly revenue growth. In this environment? 
Via The Motley Fool
Topics Bonds Government
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Why Novo Nordisk Stock Just Slipped
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price. 
Via The Motley Fool
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals. 
Via Benzinga
Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes
The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline. 
Via Stocktwits
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Via The Motley Fool
Is It Time to Buy the Dip in Novo Nordisk Stock?
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing 
Via MarketBeat
Topics Government
Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds
Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access. 
Via Benzinga
Topics Economy
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases. 
Via Benzinga
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing
The deal is worth up to $2.2 billion, including more than $200 million in upfront and near-term payments. 
Via Investor's Business Daily
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled
Septerna CEO Jeffrey Finer said that the collaboration allows the company to create multiple oral medicines and provides the operational flexibility and resources to advance its portfolio of other... 
Via Stocktwits
Topics Artificial Intelligence
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government
Is the Fed on the Right Track?
Via The Motley Fool
Topics Economy World Trade
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
Big News! U.S. and China Trade Deal Shakes Up Markets
Stocks are soaring today on the hope that the trade tensions between the U.S. and China are behind us. 
Via The Motley Fool
Topics World Trade
Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders
Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders. 
Via Benzinga
Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims'
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main... 
Via Benzinga
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.